What is he best known for?
The fields of study he is best known for:
- Gene
- Internal medicine
- DNA
Peter K. Kaiser spends much of his time researching Ophthalmology, Visual acuity, Surgery, Macular degeneration and Choroidal neovascularization.
His Ophthalmology study combines topics from a wide range of disciplines, such as Retinopathy and Aflibercept.
He focuses mostly in the field of Aflibercept, narrowing it down to topics relating to Pro re nata and, in certain cases, Pegaptanib.
He studied Visual acuity and Diabetic retinopathy that intersect with Laser coagulation and Optometry.
He interconnects Eye disease, Ranibizumab and Age related in the investigation of issues within Macular degeneration.
His Ranibizumab research focuses on Vascular endothelial growth factor and how it relates to Oncology.
His most cited work include:
- Ranibizumab for Neovascular Age-Related Macular Degeneration (4367 citations)
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration (2644 citations)
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. (1329 citations)
What are the main themes of his work throughout his whole career to date?
Peter K. Kaiser mainly focuses on Ophthalmology, Macular degeneration, Visual acuity, Surgery and Immune system.
His Ophthalmology study frequently links to other fields, such as Diabetic retinopathy.
The Macular degeneration study combines topics in areas such as Ranibizumab, Aflibercept, Age related and Clinical trial.
Peter K. Kaiser specializes in Visual acuity, namely Fluorescein angiography.
He works in the field of Surgery, namely Eye disease.
His work carried out in the field of Cytokine brings together such families of science as Chemokine and Microbiology.
He most often published in these fields:
- Ophthalmology (32.17%)
- Macular degeneration (14.84%)
- Visual acuity (13.59%)
What were the highlights of his more recent work (between 2015-2021)?
- Ophthalmology (32.17%)
- Visual acuity (13.59%)
- Macular degeneration (14.84%)
In recent papers he was focusing on the following fields of study:
Ophthalmology, Visual acuity, Macular degeneration, In patient and Surgery are his primary areas of study.
His research integrates issues of Retina and Diabetic macular edema in his study of Ophthalmology.
The concepts of his Visual acuity study are interwoven with issues in Randomized controlled trial, Aflibercept and Retrospective cohort study.
His Retrospective cohort study research incorporates themes from Retinal Vein and Occlusion.
Peter K. Kaiser focuses mostly in the field of Macular degeneration, narrowing it down to matters related to Adverse effect and, in some cases, Clinical trial.
His research related to Vitrectomy and Epiretinal membrane might be considered part of Surgery.
Between 2015 and 2021, his most popular works were:
- Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies (152 citations)
- Choroidal neovascularisation on optical coherence tomography angiography in punctate inner choroidopathy and multifocal choroiditis (57 citations)
- Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. (44 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- DNA
His main research concerns Ophthalmology, Visual acuity, Macular degeneration, Fluorescein angiography and Surgery.
His study in Ophthalmology is interdisciplinary in nature, drawing from both Occlusion, Retina and Prospective cohort study.
The various areas that Peter K. Kaiser examines in his Visual acuity study include Retinal, Randomized controlled trial, Retrospective cohort study and Clinical trial.
Peter K. Kaiser works in the field of Macular degeneration, focusing on Choroidal neovascularization in particular.
His Fluorescein angiography research is multidisciplinary, incorporating elements of Ranibizumab and Aflibercept.
His study in the field of Epiretinal membrane and Investigational Device also crosses realms of Outcome measures.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
